I.z

Areas of consolidation

(Fr: foyers de condensation). See also under BOOP/organizing pneumonia, eosinophilic pneumonia, and in the Imaging section (XVI).

Last update : 01/01/1970
 

Causative drugs

7

Amiodarone

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.at I - Interstitial/parenchymal lung disease
I.at - Amiodarone pulmonary toxicity - Amiodarone lung
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.l II - Pulmonary edema - Acute lung injury - ARDS
II.l - Postoperative ARDS
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
VI.a VI - Pulmonary vasculopathies
VI.a - Venous thrombosis/thromboembolism - Pulmonary embolism
VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension
VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory depression-Hypoventilation-Bradypnea (See also under XIe)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis - Anaphylactoid reaction
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XI.f XI - Miscellaneous
XI.f - Pseudocyanotic skin discoloration (see also XIa, XIVa, XIVb)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock
XII.p XII - Cardiovascular involvement / toxicity
XII.p - QT prolongation
XII.t XII - Cardiovascular involvement / toxicity
XII.t - Torsades de pointe
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm
XII.au XII - Cardiovascular involvement / toxicity
XII.au - Heart failure (thyrotoxicosis-, thyroid storm-mediated)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.m XV - Pathology
XV.m - Path: Lymphoid hyperplasia - LIP-pattern
XV.o XV - Pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis)
XV.r XV - Pathology
XV.r - Path: Smudged geographic necrosis
XV.ao XV - Pathology
XV.ao - Path: Pleuritis, pleural fibrosis
XV.bt XV - Pathology
XV.bt - Path: Histiocytic proliferation
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.s XVI - Imaging
XVI.s - Imaging: An area or areas of involvement with high attenuation numbers or metallic density
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.aa XVI - Imaging
XVI.aa - Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
XVI.bq XVI - Imaging
XVI.bq - Imaging: A pattern consistent with pleuroparenchymal fibroelastosis
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVIII.b XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.b - Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT
XVIII.k XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.k - Eye-catcher: An electron-dense liver on unenhanced CT
XVIII.p XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.p - Eye-catcher: An electron-dense ('white') thyroid
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
XIX.e XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages
XIX.m XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.m - BAL: A normal cell differential
XIX.p XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.p - BAL: Lamellar bodies in AM on EM
3

Hydrocarbons (petrochemicals: petroleum, petrolatum, paraffin, vaseline, naphta, jet fuels (kerosene), Diesel, gasoil), ointments, variegated oils, butter). P.o.

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.j I - Interstitial/parenchymal lung disease
I.j - Lipoid pneumonia, exogenous
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.ae I - Interstitial/parenchymal lung disease
I.ae - Hydrocarbon pneumonitis
I.af I - Interstitial/parenchymal lung disease
I.af - Chemical (toxic) pneumonitis
I.ag I - Interstitial/parenchymal lung disease
I.ag - Fire-eater's lung or -pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis
IV.k IV - Airway involvement
IV.k - Bronchiectasis
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VIII.d VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic facial and/or airway injury
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.s XI - Miscellaneous
XI.s - Sniffing death - Death from inhalation of compound
XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
XV.as XV - Pathology
XV.as - Path: Fire eater's lung
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.ah XVI - Imaging
XVI.ah - Imaging: Pneumatoceles (see also XVIaf)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.h XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.h - BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages
4

Leflunomide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRESS - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Paraffin - Vaseline - Oil - Lipids (Mineral or other). P.o./aspirated

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified)
I.j I - Interstitial/parenchymal lung disease
I.j - Lipoid pneumonia, exogenous
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.ap I - Interstitial/parenchymal lung disease
I.ap - Paraffinoma - Lipidoma (ELP in the form of a nodule or mass)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XV.p XV - Pathology
XV.p - Path: Exogenous lipoid pneumonia
XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.r XVI - Imaging
XVI.r - Imaging: An area or areas of involvement with low attenuation numbers
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.z XVI - Imaging
XVI.z - Imaging: A large nodule or a mass
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XVIII.r XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.r - Eye catcher: A milky, cloudy or lumpy BAL fluid
XIX.h XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.h - BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages
XIX.j XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.j - BAL: Free exogenous lipids in supernatant
XXIV.f XXIV - Veterinary medicine
XXIV.f - Veterinary: Exogenous lipoid pneumonia
2

Radiation therapy to the breast

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
2

Silicone (fluid, liquid)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.al I - Interstitial/parenchymal lung disease
I.al - Silicone pneumonitis - 'Silicone lung'
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH)
VI.m VI - Pulmonary vasculopathies
VI.m - Silicone embolism (SE) - SE syndrome
VII.k VII - Mediastinal involvement
VII.k - Mediastinal silicone infiltration/siliconoma
VIII.k VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.k - Submucosal airway petechiae/hemorrhage
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.aa XI - Miscellaneous
XI.aa - CNS symptoms or involvement, stroke
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.bn XV - Pathology
XV.bn - Path: Silicone in lung tissue, pulmonary vasculature, or lymph nodes
XV.bo XV - Pathology
XV.bo - Path: Siliconoma
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution
XVI.ax XVI - Imaging
XVI.ax - Imaging: Foreign body pulmonary embolism
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XIX.d XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage
XIX.l XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.l - BAL: Silicone globules in macrophages
2
1